Double-blind co-operative trial to compare trimethoprim-sulfalene and co-trimoxazole in the treatment of lower respiratory tract infections.

Abstract

Two fixed trimethoprim-sulfonamide combinations were compared in a clinical trial for their effectiveness and safety in the treatment of patients with acute lower respiratory tract infections (pneumonia, bronchopenumonia, purulent tracheobronchitis, ect.). 46 in-patients were randomly allocated to Kelfiprim (trimethoprim 250 mg + sulfalene (sulfamethopyrazine) 200 mg) or to co-trimoxazole (trimethoprim 320 mg + sulfamethoxazole 1600 mg) and were treated for 1-2 weeks under double-blind conditions. Assessment of effectiveness was based on daily follow-up of subjective and objective signs and symptoms, on changes in X-ray picture, and on microbiological and laboratory findings. Response to therapy was excellent or good in 86% of patients receiving Kelfiprim and in 79% of those given cotrimoxazole. Transient side-effects were observed in three patients under Kelfiprim (two allergic reactions and one G.I. complaint) and in one under co-trimoxazole (altered kidney function).

• Authors: R Ferlinz, J Lorenz, K Micka, P G Noseda, B Pfister, F Trendelenburg
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 33 Issue 11 Pg. 1609-12 ( 1983) ISSN: 0004-4172 [Print] Germany
• PMID: 6362676 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Drug Combinations
• Sulfanilamides
• kelfiprim
• Trimethoprim, Sulfamethoxazole Drug Combination
• Trimethoprim
• Sulfamethoxazole
• Sulfalene

Topics

• Adult
• Aged
• Blood Cell Count
• Blood Urea Nitrogen
• Clinical Trials as Topic
• Double-Blind Method
• Drug Combinations (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Respiratory Tract Infections (drug therapy, microbiology)
• Sulfalene (therapeutic use)
• Sulfamethoxazole (therapeutic use)
• Sulfanilamides (therapeutic use)
• Trimethoprim (therapeutic use)
• Trimethoprim, Sulfamethoxazole Drug Combination